Unveiling the Key Aspects of Gilead Sciences

By Naomi Wentworth • Tuesday, April 29 15:14 • Permanent Link

Gilead Sciences logged a -0.8% change during today's afternoon session, and is now trading at a price of $105.52 per share. The S&P 500 index moved 1.0%. GILD's trading volume is 3,658,745 compared to the stock's average volume of 9,627,093.

Gilead Sciences trades -7.58% away from its average analyst target price of $114.17 per share. The 26 analysts following the stock have set target prices ranging from $92.0 to $140.0, and on average have given Gilead Sciences a rating of buy.

If you are considering an investment in GILD, you'll want to know the following:

Gilead Sciences's current price is 819.1% above its Graham number of $11.48, which implies that at its current valuation it does not offer a margin of safety
Gilead Sciences has moved 63.1% over the last year, and the S&P 500 logged a change of 9.8%
Based on its trailing earnings per share of 4.76, Gilead Sciences has a trailing 12 month Price to Earnings (P/E) ratio of 22.2 while the S&P 500 average is 29.3
GILD has a forward P/E ratio of 14.2 based on its forward 12 month price to earnings (EPS) of $7.43 per share
Its Price to Book (P/B) ratio is 6.89 compared to its sector average of 3.19
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Based in Foster City, the company has 17,600 full time employees and a market cap of $131.37 Billion. Gilead Sciences currently returns an annual dividend yield of 2.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.